News

Unique conference on empowering personalised medicine and health research

- An impressive list of Dutch research organisations has joined forces on personalised medicine: BBMRI-NL, DTL/ELIXIR-NL, EATRIS, Federa/COREON, FHI, Federatie Medisch Specialist, NFU, ZonMw, NWO, Diabetesfonds, Hartstichting, Reumafonds, MLDS, Inspire2Live, SURFSara, and the Top Sector Life Sciences & Health. As a first step, they organised the conference Empowering Personalised Medicine and Health Research on 4 November 2015.

Utrecht Science Park opens first iLab

- Vrijdag 13 november is het eerste innovatielaboratorium (iLab) bij Hogeschool Utrecht op het Utrecht Science Park geopend.

New generation antibiotics to treat drug resistant infections

- Synamp Pharmaceuticals announced as winner of the Health~Holland Venture Challenge Fall Edition.

Health~Holland Update, November 2015

- We are pleased to publish the fifth edition of the bimonthly Health~Holland Update, our magazine that brings you the latest insights and developments from Health~Holland (Top Sector Life Sciences & Health).

Hubrecht Institute partners up with Top Sector LSH

- The Hubrecht Institute enter a public-private partnership with the Top Sector Life Sciences & Health.

Schippers introduces Health Deals

- Minister Edith Schippers (VWS) heeft vandaag mede namens haar collega Henk Kamp (EZ) de aftrap gegeven voor het aangaan van ‘Health Deals’. Zij deed dit door een digitaal loket voor informatie over - en ondersteuning bij - het opstarten van deze zorgprojecten te openen.

Hechten met één hand, mede dankzij Innovatiekrediet

- Zorg voor een goede analyse van de markt en van de klantwaarde. Deze les leerde Mellon Medical. Het bedrijf ontwikkelt de Switch, een precisie-hechtinstrument voor chirurgen.

Pharma Boardroom Interview Hans Schikan

- Hans Schikan offers insights into the flourishing Dutch life sciences sector and the attractiveness of the local eco-system, citing a combination of the right science and the right attitude of people as the key formula for success.

Hercules Receives €3.5 Million EUROSTARS Grant for Further Development of a New Drug for Triple Negative Breast Cancer

- Hercules Pharmaceuticals BV, a biopharmaceutical company developing an innovative treatment for women with Triple Negative Breast Cancer (TNBC), has been awarded a € 3,5 million Eurostars grant for the development of its lead drug CB7993113 for treatment of TNBC.

InteRNA Technologies Secures Final Extension Series A Financing and Strengthens Its Supervisory Board

- InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces the closing of an equity financing round. This final extension of its Series A was co-led by new investors INKEF Capital and Aglaia Oncology Fund II. Existing shareholders also participated in this round, bringing the total Series A funding to US$ 10.5 million.